Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: An improvement method

Obesity

Volumn 20, Issue 2, 2012, Pages 444-452

  Xia, Ming Feng ^a   Yan, Hong Mei ^a   He, Wan Yuan ^a   Li, Xiao Ming ^a   Li, Chao Lun ^a   Yao, Xiu Zhong ^a   Li, Ruo Kun ^a   Zeng, Meng Su ^a   Gao, Xin ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; ECHOGRAPHY; FATTY LIVER; FEMALE; HEPATIC RENAL ECHO INTENSITY RATIO; HEPATOBILIARY PARAMETERS; HUMAN; LIVER FAT CONTENT; MALE; PHANTOM; PREDICTIVE VALUE; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; ULTRASOUND HEPATIC ECHO INTENSITY ATTENUATION RATE;

ADIPOSE TISSUE; ADOLESCENT; ADULT; AGED; COST-BENEFIT ANALYSIS; FATTY LIVER; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; KIDNEY; LIVER; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; OBESITY; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84856274286     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.302     Document Type: Article

References (35)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657. (Pubitemid 34533559)
2. Williams R. Global challenges in liver disease. Hepatology 2006;44: 521-526. (Pubitemid 44433707)
3. Bedogni G, Miglioli L, Masutti F et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
4. Fan JG, Zhu J, Li XJ et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai, China. J Hepatol 2005;43:508-514. (Pubitemid 41111434)
5. Amarapurkar DN, Hashimoto E, Lesmana LA et al.; Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007;22:788-793. (Pubitemid 46911047)
6. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-1231.
7. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455. (Pubitemid 29528333)
8. Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007;13:1579-1584. (Pubitemid 46672668)
9. Fracanzani AL, Burdick L, Raselli S et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 2008;121: 72-78.
10. Ratziu V, Charlotte F, Heurtier A et al.; LIDO Study Group. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906. (Pubitemid 40824701)
11. Syn WK, Nightingale P, Bateman JM. Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008;2:190-195. (Pubitemid 351650147)
12. Dassanayake AS, Kasturiratne A, Rajindrajith S et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. J Gastroenterol Hepatol 2009;24:1284-1288.
13. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395. (Pubitemid 39657013)
14. Thomsen C, Becker U, Winkler K et al. Quantification of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 1994;12: 487-495. (Pubitemid 24113193)
15. McPherson S, Jonsson JR, Cowin GJ et al. Magnetic resonance imaging and spectroscopy accurately estimate the severity of steatosis provided the stage of fibrosis is considered. J Hepatol 2009;51:389-397.
16. Cowin GJ, Jonsson JR, Bauer JD et al. Magnetic resonance imaging and spectroscopy for monitoring liver steatosis. J Magn Reson Imaging 2008;28:937-945.
17. Liu M, Gao X, Rao SX, Wu L, Zeng MS. [Measurement of intrahepatic triglyceride stores by 1H magnetic resonance spectroscopy: study with rat models and in patients]. Zhonghua Yi Xue Za Zhi 2008;88:531-533. (Pubitemid 351682029)
18. Szczepaniak LS, Nurenberg P, Leonard D et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-E468. (Pubitemid 40110657)
19. Strauss S, Gavish E, Gottlieb P, Katsnelson L. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007;189:W320-W323.
20. Dasarathy S, Dasarathy J, Khiyami A et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009;51:1061-1067.
21. Edens MA, van Ooijen PM, Post WJ et al. Ultrasonography to quantify hepatic fat content: validation by 1H magnetic resonance spectroscopy. Obesity (Silver Spring) 2009;17:2239-2244.
22. Webb M, Yeshua H, Zelber-Sagi S et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009;192:909-914.
23. Mancini M, Prinster A, Annuzzi G et al. Sonographic hepatic-renal ratio as indicator of hepatic steatosis: comparison with (1)H magnetic resonance spectroscopy. Metab Clin Exp 2009;58:1724-1730.
24. Thijssen JM, Starke A, Weijers G et al. Computer-aided B-mode ultrasound diagnosis of hepatic steatosis: a feasibility study. IEEE Trans Ultrason Ferroelectr Freq Control 2008;55:1343-1354.
25. Farrell GC, Chitturi S, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of nonalcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol 2007;22:775-777. (Pubitemid 46911045)
26. Langton CM, Njeh CF. The measurement of broadband ultrasonic attenuation in cancellous bone-a review of the science and technology. IEEE Trans Ultrason Ferroelectr Freq Control 2008;55:1546-1554.
27. Umchid S. Frequency dependent ultrasonic attenuation coefficient measurement. ISBME 2008:234-238.
28. Bian H, Yan H, Zeng M et al. Increased liver fat content and unfavorable glucose profiles in subjects without diabetes. Diabetes Technol Ther 2011;13:149-155.
29. Perkins NJ, Schisterman EF. The inconsistency of "optimal" cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol 2006;163:670-675.
30. Cleophas TJ, Droogendijk J, van Ouwerkerk BM. Validating diagnostic tests, correct and incorrect methods, new developments. Curr Clin Pharmacol 2008;3:70-76.
31. Stetson PF, Sommer FG, Macovski A. Lesion contrast enhancement in medical ultrasound imaging. IEEE Trans Med Imaging 1997;16:416-425. (Pubitemid 127770426)
32. Stippel G, Philips W, Govaert P. A tissue-specific adaptive texture filter for medical ultrasound images. Ultrasound Med Biol 2005;31:1211-1223. (Pubitemid 41318855)
33. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-441.
34. Belfort R, Harrison SA, Brown K et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307. (Pubitemid 44837778)
35. Petersen KF, Dufour S, Befroy D et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 2005;54:603-608. (Pubitemid 40322060)